New noncoding RNA chemical entity for heart failure with preserved ejection fraction.

  • Post author:
  • Post category:

Research Objective Modified synthetic noncoding RNA molecule Impact Heart failure with preserved ejection fraction Major Proposed Activities Lead optimizationPerform extensive preclinical testing and select a therapeutic candidate.Develop and test preliminary…

Continue ReadingNew noncoding RNA chemical entity for heart failure with preserved ejection fraction.

Human iPSC-derived chimeric antigen receptor expressing macrophages for improved cancer treatment.

  • Post author:
  • Post category:

Research Objective These studies will produce a new CAR-targeted iPSC-derived macrophage-based cell therapy product for treatment of refractory malignancies such as ovarian cancer. Impact These studies eliminate a bottleneck in…

Continue ReadingHuman iPSC-derived chimeric antigen receptor expressing macrophages for improved cancer treatment.

A universally applicable skin sheet for Dystrophic Epidermolysis Bullosa via next-generation gene editing, iPS cell technology and tissue engineering

  • Post author:
  • Post category:

Research Objective We will develop a cell therapy for a rare skin disease. Patient-derived iPS cells will be genetically corrected and differentiated into epithelial sheets to be grafted on skin…

Continue ReadingA universally applicable skin sheet for Dystrophic Epidermolysis Bullosa via next-generation gene editing, iPS cell technology and tissue engineering